发明名称 |
Drug conjugate comprising drug linked to human c-Met antibody, and use therefor |
摘要 |
The present invention relates to a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody. More specifically, the present invention relates to: a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody; a pharmaceutical composition for cancer treatment comprising the drug conjugate; and a cancer treatment method comprising a step in which the drug conjugate or pharmaceutical composition is administered to an individual. |
申请公布号 |
US9364556(B2) |
申请公布日期 |
2016.06.14 |
申请号 |
US201214360937 |
申请日期 |
2012.11.28 |
申请人 |
Korea Research Institute of Bioscience and Biotechnology;A&RT Co., Ltd. |
发明人 |
Park Young Woo;Jo Ki Won;Jo Sun Jeong;Hyun Soon Sil;Park Jae Eun;Yoo Seok Ho;Jang Myeoung Hee;Kim Hye Nan;Park Chan Woong |
分类号 |
A61K39/395;A61K47/48;C07K16/28;A61K31/704;A61K39/00 |
主分类号 |
A61K39/395 |
代理机构 |
|
代理人 |
|
主权项 |
1. An antibody-drug conjugate comprising a cytotoxic, drug conjugated to a c-Met-specific human antibody, wherein the antibody comprises:
a heavy-chain variable region comprising: i) a heavy-chain CDR1 comprising amino acids having the sequence set forth it SEQ ID NO: 1; ii) a heavy-chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 2; and iii) a heavy-chain CDR3 comprising amino acids having the sequence set forth SEQ ID NO: 3; and a light-chain variable region comprising: i) a light-chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 4; ii) a light-chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 5; and iii) a light-chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 6. |
地址 |
Dajeon KR |